News

Carmell Announces Successful Closing of $3.0 Million Private Placement

  • PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of its previously announced private placement with new and existing investors (the “Private Placement”). The Company received gross proceeds from the Private Placement of $3 million, excluding offering expenses.
    04/11/2024

Carmell Announces $3.0 Million Private Placement

  • PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced that it entered into a securities purchase agreement with new and existing investors for the issuance and sale of approximately 1,333,333 shares of its common stock in a private placement at a price of $2.25 per common share for aggregate gross proceeds of 3 million dollars before deducting offering expenses (the “Private Placement”).
    04/04/2024
Profitability
Dividends
Income Statement
Balance Sheet
Cash Flow Statement
Symbol Frequently Asked Questions

Carmell Therapeutics Corporation (CTCX) can hold. Click on Rating Page for detail.

The price of Carmell Therapeutics Corporation (CTCX) is 1.93 and it was updated on 2024-07-02 13:00:43.

Currently Carmell Therapeutics Corporation (CTCX) is in undervalued.

News
    
News

Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction

  • PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the successful closing of the previously announced sale of its wholly owned subsidiary, Axolotl Biologix (“AxoBio”) to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and cancellation of $8 million in notes payable.
    Wed, Mar. 27, 2024

Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

  • PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix (“AxoBio”) to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. “The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and continuing over Summer 2024,” said Rajiv Shukla, Chief Executive Officer of Carmell.
    Wed, Mar. 20, 2024

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

  • PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced it will host an Investor Webinar titled “Unveiling the Secretome: On the Eve of Product Launch” on March 20, 2024 at 3:00 PM ET to discuss Carmell Secretome™, the biggest technological revolution in regenerative skin and haircare to the fast-growing ~$500 billion aesthetics industry. To register, click here.
    Mon, Mar. 18, 2024

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

  • PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they have completed product development of their Gold Limited Edition Exclusive (G.L.E.E.) product for commercial launch in March 2024.
    Mon, Feb. 26, 2024

Carmell Corp Announces Addition of Scott Frisch and Gilles Spenlehauer to Board of Directors

  • PITTSBURGH, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a human biomaterials company (“Carmell”), today announced the addition of two independent directors to their Board.
    Thu, Nov. 16, 2023
SEC Filings
SEC Filings

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 09/06/2023

Carmell Therapeutics Corporation (CTCX) - 8-K/A - Current report

  • SEC Filings
  • 08/14/2023

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 08/14/2023

Carmell Therapeutics Corporation (CTCX) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/14/2023

Carmell Therapeutics Corporation (CTCX) - S-1

  • SEC Filings
  • 08/07/2023

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 08/01/2023

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 07/14/2023

Carmell Therapeutics Corporation (CTCX) - 25-NSE

  • SEC Filings
  • 07/14/2023

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 07/12/2023

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 07/10/2023

Carmell Therapeutics Corporation (CTCX) - 425

  • SEC Filings
  • 07/10/2023

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 07/06/2023

Carmell Therapeutics Corporation (CTCX) - 425

  • SEC Filings
  • 07/06/2023

Carmell Therapeutics Corporation (CTCX) - 424B3

  • SEC Filings
  • 06/23/2023

Carmell Therapeutics Corporation (CTCX) - S-4/A

  • SEC Filings
  • 06/20/2023

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 03/31/2023

Carmell Therapeutics Corporation (CTCX) - SC 13G/A

  • SEC Filings
  • 03/23/2023

Carmell Therapeutics Corporation (CTCX) - S-4/A

  • SEC Filings
  • 03/23/2023

Carmell Therapeutics Corporation (CTCX) - SC 13G

  • SEC Filings
  • 03/21/2023

Carmell Therapeutics Corporation (CTCX) - 10-K - Current report

  • SEC Filings
  • 03/17/2023

Carmell Therapeutics Corporation (CTCX) - SC 13G/A

  • SEC Filings
  • 02/14/2023

Carmell Therapeutics Corporation (CTCX) - SC 13G

  • SEC Filings
  • 02/14/2023

Carmell Therapeutics Corporation (CTCX) - S-4

  • SEC Filings
  • 02/14/2023

Carmell Therapeutics Corporation (CTCX) - SC 13G/A

  • SEC Filings
  • 02/06/2023

Carmell Therapeutics Corporation (CTCX) - SC 13G/A

  • SEC Filings
  • 02/03/2023

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 01/04/2023

Carmell Therapeutics Corporation (CTCX) - 425

  • SEC Filings
  • 01/04/2023

Carmell Therapeutics Corporation (CTCX) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/10/2022

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 10/11/2022

Carmell Therapeutics Corporation (CTCX) - 10-Q/A - Quarterly Report

  • SEC Filings
  • 09/13/2022

Carmell Therapeutics Corporation (CTCX) - 10-Q/A - Quarterly Report

  • SEC Filings
  • 09/12/2022

Carmell Therapeutics Corporation (CTCX) - 8-K/A - Current report

  • SEC Filings
  • 09/09/2022

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 09/09/2022

Carmell Therapeutics Corporation (CTCX) - 10-Q - Quarterly Report

  • SEC Filings
  • 08/10/2022

Carmell Therapeutics Corporation (CTCX) - 10-Q - Quarterly Report

  • SEC Filings
  • 05/20/2022

Carmell Therapeutics Corporation (CTCX) - NT 10-Q - Quarterly Report

  • SEC Filings
  • 05/16/2022

Carmell Therapeutics Corporation (CTCX) - 10-K - Current report

  • SEC Filings
  • 04/15/2022

Carmell Therapeutics Corporation (CTCX) - NT 10-K - Current report

  • SEC Filings
  • 03/31/2022

Carmell Therapeutics Corporation (CTCX) - SC 13G/A

  • SEC Filings
  • 02/14/2022

Carmell Therapeutics Corporation (CTCX) - SC 13G

  • SEC Filings
  • 02/14/2022

Carmell Therapeutics Corporation (CTCX) - SC 13G/A

  • SEC Filings
  • 02/03/2022

Carmell Therapeutics Corporation (CTCX) - 10-Q - Quarterly Report

  • SEC Filings
  • 11/22/2021

Carmell Therapeutics Corporation (CTCX) - NT 10-Q - Quarterly Report

  • SEC Filings
  • 11/15/2021

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 09/15/2021

Carmell Therapeutics Corporation (CTCX) - 10-Q - Quarterly Report

  • SEC Filings
  • 09/13/2021

Carmell Therapeutics Corporation (CTCX) - NT 10-Q - Quarterly Report

  • SEC Filings
  • 09/09/2021

Carmell Therapeutics Corporation (CTCX) - SC 13G

  • SEC Filings
  • 08/06/2021

Carmell Therapeutics Corporation (CTCX) - SC 13G

  • SEC Filings
  • 08/05/2021

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 08/04/2021

Carmell Therapeutics Corporation (CTCX) - SC 13G

  • SEC Filings
  • 08/03/2021

Carmell Therapeutics Corporation (CTCX) - SC 13G

  • SEC Filings
  • 08/02/2021

Carmell Therapeutics Corporation (CTCX) - 8-K - Current report

  • SEC Filings
  • 07/29/2021

Carmell Therapeutics Corporation (CTCX) - 424B4

  • SEC Filings
  • 07/27/2021

Carmell Therapeutics Corporation (CTCX) - EFFECT

  • SEC Filings
  • 07/26/2021

Carmell Therapeutics Corporation (CTCX) - CORRESP

  • SEC Filings
  • 07/22/2021

Carmell Therapeutics Corporation (CTCX) - S-1/A

  • SEC Filings
  • 07/19/2021

Carmell Therapeutics Corporation (CTCX) - CORRESP

  • SEC Filings
  • 07/19/2021

Carmell Therapeutics Corporation (CTCX) - UPLOAD

  • SEC Filings
  • 07/16/2021

Carmell Therapeutics Corporation (CTCX) - S-1/A

  • SEC Filings
  • 07/12/2021

Carmell Therapeutics Corporation (CTCX) - S-1/A

  • SEC Filings
  • 06/17/2021

Carmell Therapeutics Corporation (CTCX) - CORRESP

  • SEC Filings
  • 03/24/2021

Carmell Therapeutics Corporation (CTCX) - CORRESP

  • SEC Filings
  • 03/23/2021

Carmell Therapeutics Corporation (CTCX) - CERT

  • SEC Filings
  • 03/23/2021

Carmell Therapeutics Corporation (CTCX) - CORRESP

  • SEC Filings
  • 03/18/2021

Carmell Therapeutics Corporation (CTCX) - S-1/A

  • SEC Filings
  • 03/16/2021

Carmell Therapeutics Corporation (CTCX) - 8-A12B

  • SEC Filings
  • 03/16/2021

Carmell Therapeutics Corporation (CTCX) - S-1

  • SEC Filings
  • 03/04/2021

Carmell Therapeutics Corporation (CTCX) - DRS

  • SEC Filings
  • 02/02/2021
More Headlines
News

Moonshot Client Axolotl Announces Merger with Carmell Therapeutics, Elevating the Field of Regenerative Medicine

  • FLAGSTAFF, Ariz. , Sept. 12, 2023 /PRNewswire/ -- Moonshot is excited to announce that its incubator client, Axolotl Biologix, based in its NACET Flagstaff, Arizona campus, has finalized a merger with Carmell Therapeutics (Nasdaq: CTCX).
  • 09/12/2023

Carmell Corporation Announces Completion of Post-Merger Integration with Axolotl Biologix and New Organizational Structure Aligned with Focus on Aesthetics

  • PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative care company, today announced the completion of post-merger integration with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company (“Axolotl”).
  • 09/05/2023

Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

  • PITTSBURGH & FLAGSTAFF, Ariz.--(BUSINESS WIRE)--Carmell Corporation (Nasdaq: CTCX) (“Carmell”), a regenerative care company today announced the successful closing of the previously announced merger with Flagstaff-based Axolotl Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and orthopedic indications (“Axolotl”). As previously indicated, the initial merger consideration consists of $8 million in cash and $57 million in CTCX comm.
  • 08/09/2023

Best Penny Stocks To Buy? 6 To Watch Before Next Week

  • Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.
  • 07/28/2023
Unlock
CTCX Ratings Summary
CTCX Quant Ranking